Maze Therapeutics Inc
MAZE
查看详细走势图
42.100USD
+0.020+0.05%
收盘 12/26, 16:00（美东）报价延迟15分钟
2.02B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+0.05%
5天
+0.94%
1月
+10.79%
6月
+230.46%
今年开始到现在
0.00%
1年
0.00%
查看详细走势图
TradingKey Maze Therapeutics Inc股票评分
单位: USD 更新时间: 2025-12-26操作建议
Maze Therapeutics Inc当前公司基本面数据相对非常健康，增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名39/404位。机构持股占比非常高，近一月多位分析师给出公司评级为强力买入。最高目标价43.25。中期看，股价处于上升通道。近一个月，市场表现较强，技术面和基本面综合得分较高，较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Maze Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
9
位分析师
强力买入
评级
43.250
目标均价
+4.32%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Maze Therapeutics Inc亮点
亮点风险
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
业绩转盈
公司业绩转盈，最新年度盈利美元
估值低估
公司最新PE估值-16.45，处于3年历史低位
机构减仓
最新机构持股39.53M股，环比减少0.49%
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值1.93K
Maze Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Maze Therapeutics Inc简介
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
公司代码MAZE
公司Maze Therapeutics Inc
CEOColoma (Jason V)
网址https://www.mazetx.com/
常见问题
Maze Therapeutics Inc(MAZE)的当前股价是多少？
Maze Therapeutics Inc(MAZE)的当前股价是 42.100。
Maze Therapeutics Inc的股票代码是什么？
Maze Therapeutics Inc的股票代码是MAZE。
Maze Therapeutics Inc股票的52周最高点是多少？
Maze Therapeutics Inc股票的52周最高点是43.290。
Maze Therapeutics Inc股票的52周最低点是多少？
Maze Therapeutics Inc股票的52周最低点是6.710。
Maze Therapeutics Inc的市值是多少？
Maze Therapeutics Inc的市值是2.02B。
Maze Therapeutics Inc的净利润是多少？
Maze Therapeutics Inc的净利润为3.40M。
现在Maze Therapeutics Inc(MAZE)的股票是买入、持有还是卖出？
根据分析师评级，Maze Therapeutics Inc(MAZE)的总体评级为--，目标价格为43.250。
Maze Therapeutics Inc(MAZE)股票的每股收益（EPS TTM）是多少
Maze Therapeutics Inc(MAZE)股票的每股收益（EPS TTM）是-2.559。
相关品种
